GlassScriptPhysician profile
Bhupendra Tolia
NPI 1508866567
$3,225.70
in general payments reported to CMS, 2019-2025
21 companies · $63.96 in 2025
The $63.96 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $34.69 · 2021: $299 · 2022: $1,127 · 2023: $321 · 2024: $778 · 2025: $63.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.28 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urovant Sciences INC | $873.25 | 2021-2022 | |
| Pfizer INC. | $574.16 | 2019-2024 | |
| Janssen Biotech, INC. | $466.04 | 2019-2024 | Akeega, Erleada |
| Sumitomo Pharma America, INC. | $406.75 | 2023-2025 | Gemtesa |
| Astellas Pharma US INC | $169.35 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2024 | Uzedy |
| Amarin Pharma, INC. | $102.98 | 2019 | |
| Myovant Sciences INC. | $62.14 | 2021 | |
| Amgen INC. | $54.68 | 2019-2020 | |
| Abbvie INC. | $46.22 | 2019 | |
| Taiho Oncology, INC. | $33.63 | 2021 | |
| Merck Sharp & Dohme LLC | $30.84 | 2019 | |
| Myriad Genetic Laboratories, INC. | $27.74 | 2023 | Prolaris |
| Verity Pharmaceuticals INC. | $24.54 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $23.20 | 2019 | |
| Seagen INC. | $23.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $21.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.84 | 2021 | |
| Teleflex LLC | $16.48 | 2023 | Urolift |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bhupendra Tolia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.